Villegas Eloy A, Alcon Encarna, Rubio Elena, Marín José M, Artal Pablo
From Laboratorio de Optica (Villegas, Alcon, Artal), Departamento de Física, Universidad de Murcia, and Servicio de Oftalmología (Rubio, Marín), Hospital Universitario Virgen de la Arrixaca El Palmar, Murcia, Spain.
From Laboratorio de Optica (Villegas, Alcon, Artal), Departamento de Física, Universidad de Murcia, and Servicio de Oftalmología (Rubio, Marín), Hospital Universitario Virgen de la Arrixaca El Palmar, Murcia, Spain.
J Cataract Refract Surg. 2014 Jul;40(7):1075-84.e2. doi: 10.1016/j.jcrs.2013.10.046.
To evaluate efficacy, predictability, and stability of refractive treatments using light-adjustable intraocular lenses (IOLs).
University Hospital Virgen de la Arrixaca, Murcia, Spain.
Prospective nonrandomized clinical trial.
Eyes with a light-adjustable IOL (LAL) were treated with spatial intensity profiles to correct refractive errors. The effective changes in refraction in the light-adjustable IOL after every treatment were estimated by subtracting those in the whole eye and the cornea, which were measured with a Hartmann-Shack sensor and a corneal topographer, respectively. The refractive changes in the whole eye and light-adjustable IOL, manifest refraction, and visual acuity were obtained after every light treatment and at the 3-, 6-, and 12-month follow-ups.
The study enrolled 53 eyes (49 patients). Each tested light spatial pattern (5 spherical; 3 astigmatic) produced a different refractive change (P<.01). The combination of 2 light adjustments induced a maximum change in spherical power of the light-adjustable IOL of between -1.98 diopters (D) and +2.30 D and in astigmatism of up to -2.68 D with axis errors below 9 degrees. Intersubject variability (standard deviation) ranged between 0.10 D and 0.40 D. The 2 required lock-in procedures induced a small myopic shift (range +0.01 to +0.57 D) that depended on previous adjustments.
Light-adjustable IOL implantation achieved accurate refractive outcomes (around emmetropia) with good uncorrected distance visual acuity, which remained stable over time. Further refinements in nomograms and in the treatment's protocol would improve the predictability of refractive and visual outcomes with these IOLs.
No author has a financial or proprietary interest in any material or method mentioned.
评估使用光可调人工晶状体(IOL)进行屈光治疗的疗效、可预测性和稳定性。
西班牙穆尔西亚的阿利克斯卡圣母大学医院。
前瞻性非随机临床试验。
对植入光可调IOL(LAL)的眼睛采用空间强度分布进行治疗以矫正屈光不正。每次治疗后,通过分别用哈特曼-夏克传感器和角膜地形图仪测量全眼和角膜的屈光变化,估算光可调IOL的有效屈光变化。每次光治疗后以及在3个月、6个月和12个月随访时,获取全眼和光可调IOL的屈光变化、显验光和视力。
该研究纳入了53只眼(49例患者)。每个测试的光空间模式(5种球面;3种散光)产生不同的屈光变化(P<0.01)。两次光调整的组合使光可调IOL的球镜度数最大变化在-1.98屈光度(D)至+2.30 D之间,散光变化可达-2.68 D,轴位误差低于9度。受试者间变异性(标准差)在0.10 D至0.40 D之间。所需的两次锁定程序引起了小的近视偏移(范围为+0.01至+0.57 D),这取决于先前的调整。
光可调IOL植入实现了准确的屈光结果(接近正视),未矫正远视力良好,且随时间保持稳定。在列线图和治疗方案方面的进一步改进将提高这些IOL屈光和视觉结果的可预测性。
没有作者对文中提及的任何材料或方法有财务或专利权益。